Adicet Bio (ACET)
(Delayed Data from NSDQ)
$1.45 USD
-0.11 (-7.05%)
Updated May 29, 2024 04:00 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
Brokerage Reports
Adicet Bio, Inc. [ACET]
Reports for Purchase
Showing records 1 - 20 ( 99 total )
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
EHA 2024 Abstract Roundup for Covered Companies
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
ASGCT 2024: ADI-270 Showing High Target Sensitivity
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE- ASGCT 2024 Abstract Roundup for Covered Companies
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
4Q23 Results; Phase 1 GLEAN Study Continues to Enroll MCL Patients; ADI-001 Expanding into Autoimmune Indications
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
Q4/FY23 Financials; ADI-001 and ADI-270 Remain on Track
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
Model Update Following Raise; Lowering PT to $10
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
Highlights From Clinical Pipeline and Corporate Outlook Conference Call
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
ADI-001 Expands to II via Lupus Nephritis; MCL New Focus
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
ADI-001 Expansion, Persistence, and Pharmacodynamic Profile Data From Phase 1 Study Highlighted at ASH 2023
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
ASH 2023 Weekend Roundup for Covered Companies
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
3Q23 Results; ADI-001 Phase 1 Update Expected 2H24; Evaluating Pivotal Phase 2 Study
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
Q3 Financials, ADI-001 Jumps After the CAR(-T); ADI-270 Next up
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
EORTC-NCI-AACR 2023: Roundup for Covered Companies
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology- EORTC-NCI-AACR 2023 Abstract Roundup for Covered Companies
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
2Q23 Results; ADI-001 Clinical Update Expected in 2H24; IND Filing for ADI-925 Expected 2H23
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E